Liver Cancer malady

MedlinePlus: Your liver is the largest organ inside your body. it filters harmful substances from the blood, digests fats from food and stores the sugar that your body uses for energy. primary liver cancer starts in the liver. metastatic liver cancer starts somewhere else and spreads to your liver. risk factors for primary liver cancer include having hepatitis having cirrhosis, or scarring of liver being male low weight at birth symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. however, you may not have symptoms and the cancer may not be found until it is advanced. this makes it harder to treat. treatment options include surgery, radiation, chemotherapy or liver transplantation. nih: national cancer institute²³

MalaCards: Liver Cancer, also known as primary malignant neoplasm of liver, is related to carcinoma and hepatocellular cancer. An important gene associated with Liver Cancer is DLC1 (deleted in liver cancer 1), and among its related pathways are Apoptosis and Autophagy and Akt Signaling. The drugs prednisone and prednisolone tebutate and the compounds leucine and carbon have been mentioned in the context of this disorder. Affiliated tissues include the liver, spleen and small intestine, and related mouse phenotypes are hematopoietic system and embryogenesis.

Disease Ontology: A gastrointestinal system cancer that is located in the liver.⁶

Wikipedia: Liver cancer or hepatic cancer (from the Greek hēpar, meaning liver) is a cancer that originates in the...⁴⁴ more...

Aliases & Descriptions:

liver cancer 6 30 8 23 primary malignant neoplasm of liver 6 43 malignant hepato-biliary neoplasm 6 43 hepatic cancer 6 32 liver neoplasm 6 8 epithelial hepatic and intrahepatic bile duct neoplasm 6 malignant neoplasm of liver, not specified as primary 6 primary malignant neoplasm of liver nos (disorder) 6 malignant neoplasm of liver unspecified (disorder) 6 non-resectable primary hepatic malignant neoplasm 6 primary malignant neoplasm of liver (disorder) 6 liver and intrahepatic biliary tract carcinoma 43 resectable malignant neoplasm of the liver 6 non-resectable hepatic malignant neoplasm 43 malignant neoplasm of liver (disorder) 6 resectable malignant neoplasm of liver 6 malignant neoplasm of liver, primary 6 malignant tumor of liver (disorder) 6 hepatocellular carcinoma, adult 30

ca liver - primary (disorder) 6 neoplasm of liver (disorder) 6 malignant neoplasm of liver 6 primary tumor of the liver 30 liver cell carcinoma adult 30 primary malignant neoplasm 43 hepatocellular cancer 30 primary liver cancer 6 neoplasm metastasis 43 malignant neoplasms 43 liver cancer adult 30 ca liver - primary 6 hepatic neoplasm 6 liver neoplasms 43 neoplasms 43 secondary 6 hepatoma 30 hcc 30

Diseases related to liver cancer by text searches and GeneDecks gene sharing:

(show top 50)    (show all 1751)

id	Related Disease	Score	Top Affiliating Genes
1	carcinoma	39.1	PIK3CG, PIN1, REG1A, REG3A, RELN, KIAA1524
2	hepatocellular cancer	34.9	MYC, BMP6, BIRC5, BAX, CDKN1B, CDK4
3	hepatitis	34.9	SERPINA1, XDH, FAS, GPT, GPC3, IFNA1
4	hepatocellular carcinoma	34.5	PIK3CG, PIN1, REG1A, REG3A, RELN, SFRP2
5	hepatitis b	33.0	GPT, IFNA1, F2, ALB, CAT, TMPO
6	liver cirrhosis	32.8	SERPINA1, RAF1, RASSF1, LIF, MUC5AC, XDH
7	hyperparathyroidism	31.6	VEGFA, BAX, CDKN1A, CDKN1B, INS, FGF2
8	hepatitis c	31.4	SERPINA1, IL2, FAS, MAPK8, GPT, IFNA1
9	myelodysplastic syndrome	31.0	BOK, BIRC5, MVP, XIAP, CFLAR, FHIT
10	brain cancer	30.9	VEGFA, BAX, INSR, IL13, HRAS, AKT1
11	salivary gland cancer	30.5	SERPINB5, BIRC2, BIRC5, CHUK, CFLAR, CD151
12	hodgkin's lymphoma	30.3	PIK3CG, BIRC2, BCL2, BCL2L1, CHUK, XIAP
13	nasopharynx carcinoma	30.0	VEGFA, RASSF1, CDKN2A, CDH1, CCND1, CASP3
14	polycythemia	29.9	PIK3CG, VEGFA, BOK, RARB, BCL2L1, CDKN3
15	neuroendocrine tumor	29.8	MYCN, RAF1, RASSF1, CEACAM3, CCNB1, IGF1R
16	immunodeficiency	29.7	BMP6, ZFP36, PARP1, CFLAR, CDKN3, INS
17	ovarian mucinous neoplasm	29.5	RB1, SERPINB5, MYC, MUC5AC, CEACAM5, CEACAM3
18	porphyria cutanea tarda	29.5	BMP6, IFNA1, ALB, HMBS, CYP1A1, CYP1A2
19	tongue cancer	29.5	SERPINB5, VEGFA, MYC, BIRC5, BCL2, BAX
20	colonic neoplasm	29.4	BCL2, CDKN1A, CDH1, INS, ICAM1, TP53
21	prostatitis	29.4	PIK3CG, PIN1, RELN, KIAA1524, SFRP2, RCN1
22	amyloidosis	29.4	BCL2, FOS, INS, IL6, APOA1, FAS
23	amenorrhea	29.3	INS, APOA1, IGFBP3, ALPP, GHRL, TNFRSF11B
24	oral cavity cancer	29.2	NAT2, VEGFA, PARP1, BAX, FADD, ALDH2
25	hernia	29.1	RARB, KDR, FGF2, IGF2, F2, ALB
26	acute lymphoblastic leukemia	29.0	RB1, MYCN, BIRC2, BCL2, BCL2L1, LEF1
27	sepsis	28.9	XDH, CDKN3, IRS1, INSR, IL6, ANGPT2
28	non-hodgkin lymphoma	28.8	NAT1, NAT2, MYC, MYCN, BIRC2, BIRC5
29	thoracic cancer	28.8	KDR, CDKN1A, CASP3, CASP8, CASP9, TNFSF10
30	ovarian cancer	28.5	RB1, RBL2, CDKN1A, CDKN1B, CDKN2A, CDK4
31	polycythemia vera	28.4	PIK3CG, BOK, RARB, BCL2L1, CDKN3, IL6
32	adenoid cystic carcinoma	28.4	PIN1, SERPINB5, RASSF1, CEACAM3, CDH1, CCND1
33	breast cancer	28.4	NAT2, VEGFA, KDR, BCL2, XRCC5, MSH2
34	testicular cancer	28.3	NAT2, BMP6, RAC1, MVP, CDKN1A, CDKN1B
35	retinol binding protein	28.3	MYC, RARB, XDH, IRS1, INS, INSR
36	rectum cancer	28.3	BAX, CEACAM5, CEACAM3, TYMP, TYMS, DPYD
37	hepatoblastoma	28.3	PIK3CG, RB1, MYC, RASSF1, LIF, BID
38	hypercalcemia	28.3	BMP6, LIF, FGF2, IL2, IL6, CCND1
39	lynch syndrome	28.2	MSH2, MSH3, CDKN2A, GSTP1, APC, FAS
40	multiple myeloma	28.2	BCL2L1, FN1, IL6, MCL1, CCND1, TNFSF11
41	chronic myeloid leukemia	28.2	PIK3CG, MYC, RAF1, BIRC5, BCL2, BCL2L1
42	acute promyelocytic leukemia	28.2	PIK3CG, MYC, RARB, BCL2, BAX, CDKN1A
43	systemic lupus erythematosus	28.1	NAT2, LMNB1, CLEC12A, S100A6, FOS, IL2
44	pituitary tumor	28.1	RB1, LIF, CDKN1B, FGF2, APC, GNRHR
45	macular degeneration	28.0	NAT2, VEGFA, KHDRBS3, PARP1, KDR, MMP14
46	bile duct cancer	27.9	VEGFA, BCL2, BAX, CEACAM3, CDKN1A, CDKN2A
47	ptosis	27.9	BIRC2, BIRC5, PARP1, BCL2, BAX, XIAP
48	chronic lymphocytic leukemia	27.9	BIRC2, BIRC5, BCL2, BCL2L1, LEF1, BAX
49	malignant peripheral nerve sheath tumor	27.8	S100A6, CDKN2A, CDK4, MET, TERT, NOS2
50	inflammatory bowel disease	27.8	REG3A, SERPINA1, NAT2, CHUK, MUC5AC, XDH

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 dexamethasone, dexamethasone acetate, dexamethasone acetate pwdr [va product], dexamethasone phosphate, dexamethasone sodium phosphate, dexamethasone sodium phosphate pwdr [va product], doxorubicin hydrochloride, irinotecan, irinotecan hydrochloride, linolenic acid, mechlorethamine, mechlorethamine hydrochloride, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, prednisolone, prednisolone acetate, prednisolone acetate pwdr [va product], prednisolone pwdr [va product], prednisolone sodium phosphate, prednisolone tebutate, prednisone, prednisone pwdr [va product]

MalaCards organs/tissues related to liver cancer:

²²

FMA organs/tissues related to liver cancer:

¹¹

MGI Mouse Phenotypes related to liver cancer:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system phenotype	MP:0005397	12.7	MYCN, BID, BIRC2, ZFP36, BCL2, BCL2L1
2	embryogenesis phenotype	MP:0005380	12.0	SFRP2, RBL2, SETD2, SERPINB5, NAT1, LMNB1
3	immune system phenotype	MP:0005387	11.6	RAF1, BIRC2, ZFP36, KHSRP, PARG, KDR
4	respiratory system phenotype	MP:0005388	11.5	MYCN, LIF, LIPA, BID, INSR, SPRY2
5	craniofacial phenotype	MP:0005382	11.5	LMNB1, MYCN, LEF1, MAPK8, MAP2K1, GPC3
6	endocrine/exocrine gland phenotype	MP:0005379	11.5	REG1A, SFRP2, RBL2, PARG, YAP1, XDH
7	mortality/aging	MP:0010768	11.3	RELN, SFRP2, RB1, RBL2, SETD2, SERPINB5
8	renal/urinary system phenotype	MP:0005367	10.7	PCBD1, MYCN, RARB, LIPA, ZFP36, BCL2
9	normal phenotype	MP:0002873	10.5	SFRP2, RBL2, NAT1, VEGFA, MYC, RARB
10	reproductive system phenotype	MP:0005389	10.4	REG1A, SFRP2, RBL2, NAT1, VEGFA, MYCN
11	liver/biliary system phenotype	MP:0005370	10.3	VEGFA, MYCN, LIF, LIPA, BID, ZFP36
12	growth/size phenotype	MP:0005378	10.0	PIK3CG, PIN1, RELN, SFRP2, RB1, RBL2
13	nervous system phenotype	MP:0003631	10.0	RELN, SFRP2, RB1, RBL2, LMNB1, MYC
14	limbs/digits/tail phenotype	MP:0005371	9.8	SFRP2, RB1, RBL2, VEGFA, MYCN, RARB
15	other phenotype	MP:0005395	9.5	RARB, KDR, AXIN1, CDKN2A, ITGB1, MMP14
16	integument phenotype	MP:0010771	9.3	PIK3CG, PIN1, RELN, PCBD1, RB1, RBL2
17	behavior/neurological phenotype	MP:0005386	9.3	RELN, RB1, MYCN, RARB, LIF, LIPA
18	no phenotypic analysis	MP:0003012	9.1	SFRP2, RB1, RBL2, VEGFA, MYC, PARP1
19	digestive/alimentary phenotype	MP:0005381	9.0	RELN, RB1, VEGFA, MYC, MYCN, RARB
20	pigmentation phenotype	MP:0001186	8.6	PCBD1, RB1, MYC, RAC1, BCL2, LEF1
21	hearing/vestibular/ear phenotype	MP:0005377	8.6	RB1, MYC, RARB, PARP1, BCL2, CHUK
22	adipose tissue phenotype	MP:0005375	8.5	RB1, MYC, LIF, LIPA, ZFP36, BCL2
23	homeostasis/metabolism phenotype	MP:0005376	8.4	PIK3CG, REG1A, REG3A, SFRP2, PCBD1, RB1
24	skeleton phenotype	MP:0005390	8.4	PIK3CG, RB1, RBL2, VEGFA, MYC, MYCN
25	cellular phenotype	MP:0005384	8.3	PIK3CG, PIN1, RELN, SFRP2, RB1, RBL2
26	muscle phenotype	MP:0005369	7.7	PIK3CG, RELN, SFRP2, RB1, RBL2, VEGFA
27	cardiovascular system phenotype	MP:0005385	7.2	PIK3CG, SFRP2, RB1, RBL2, SETD2, VEGFA
28	vision/eye phenotype	MP:0005391	6.7	PIN1, RELN, PCBD1, RB1, RBL2, NAT1
29	tumorigenesis	MP:0002006	6.1	RB1, RBL2, MYC, RASSF1, BCL2, BCL2L1

Articles related to liver cancer:

(show top 50)    (show all 285)

id	Title	Authors	Year	Affiliating Genes
1	HURP expression-assisted risk scores identify prognos is distinguishable subgroups in early stage liver cancer. (22022601)	Chang M.L.... Yeh C.T.	2011	DLGAP5
2	The inhibitory effect of RNA interference on STAT3 e xpression in liver cancer cell line SMMC7721]. (21651859)	Liao W.J.... Liu J.	2011	STAT3
3	Glypican-3 targeting of liver cancer cells using mult ifunctional nanoparticles. (21303616)	Park J.O.... Zhang M.	2011	GPC3
4	Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesi on kinase (FAK). (21969587)	Li G.... Qian X.	2011	PTK2, DLC1
5	p53 codon 72 polymorphism and liver cancer susceptibi lity: a meta-analysis of epidemiologic studies. (21448428)	Chen X.... Wen T.F.	2011	TP53
6	SP1 is required for basal activation and chromatin ac cessibility of CD151 promoter in liver cancer cells. (20149781)	Wang J.... Fan Q.	2010	SP1, CD151
7	Akt phosphorylation of deleted in liver cancer 1 abro gates its suppression of liver cancer tumorigenesis and metastasis. (20600027)	Ko F.C.... Yam J.W.	2010	AKT1, DLC1
8	High expression levels of IKKalpha and IKKbeta are ne cessary for the malignant properties of liver cancer. (19728335)	Jiang R.... Sun B.	2010	CCND1, IKBKB, STAT3
9	Expression of IL-13Ralpha2 in liver cancer cells and its effect on targeted therapy of liver cancer. (19916021)	Hou L.... Hong T.	2010	IL13, IL13RA2
10	Stem cell-like micro-RNA signature driven by Myc in a ggressive liver cancer. (21059911)	Cairo S.... Buendia M.A.	2010	MYC
11	Anti-hepatitis B virus X protein in sera is one of th e markers of development of liver cirrhosis and liver cancer mediated by HBV. (19746176)	Zhang H.... Zhang X.D.	2009	RSF1
12	Meta-analysis of the efficacy of transcatheter arter ial chemoembolization combined with percutaneous ethanol injection in treating unresectable primary liver cancer (19595117)	Gu G.W.... Li X.C.	2009	AFP
13	Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. (19212669)	Shirakawa H.... Nakatsura T.	2009	GPC3
14	S-Adenosylmethionine in cell growth, apoptosis and liver cancer. (18336669)	Lu S.C.... Mato J.M.	2008	MAT2A, MAT1A
15	Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. (18759560)	Herve J.... Faivre J.	2008	REG3A
16	Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. (17593366)	Tong A.... Wei Y.	2008	AKR1B1, SOD2, HSPB1
17	Troglitazone, a peroxisome proliferator-activated receptor gamma ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. (18407589)	Zhou Y.M.... Yin Z.F.	2008	CASP3, PPARG, BIRC5
18	Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma--human and cell culture study. (18547618)	Fujii T.... Nakanuma Y.	2008	KRT7
19	Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. (18579559)	Calvisi D.F.... Pascale R.M.	2008	NOS2
20	The growth inhibition of liver cancer cells by paclit axel and the involvement of extracellular signal-regulated kinase and apoptosis . (17390065)	Okano J.... Murawaki Y.	2007	MAPK1
21	Factors related to pleural effusion following hepatectomy for primary liver cancer. (17287168)	Chu K.J.... Fu X.H.	2007	ALB, TTR, GPT
22	Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. (17517630)	Qian X.... Lowy D.R.	2007	ARHGAP1, TNS1, STARD8
23	Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice (16613672)	Zuo C.H.... Zeng L.	2006	FGF2, VEGFA, PTGS2
24	Identification of p122RhoGAP (deleted in liver cancer-1) Serine 322 as a substrate for protein kinase B and ribosomal S6 kinase in insulin-stimulated cells. (16338927)	Hers I.... Tavare J.M.	2006	AKT1, DLC1
25	Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers. (16162153)	Man X.B.... Wang H.Y.	2005	GPC3
26	Are polymorphisms of N-acetyltransferase genes susceptible to primary liver cancer in Luoyang, China? (15770721)	Zhang X.F.... Tang B.M.	2005	NAT1, NAT2
27	Alcohol and liver cancer. (16054981)	McKillop I.H.... Schrum L.W.	2005	AKR1A1
28	Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. (16217026)	Leung T.H.-Y.... Ng I.O.	2005	RHOA, ARHGAP1, STARD13
29	Promyelocytic leukemia protein-induced growth suppression and cell death in liver cancer cells. (15529177)	Son S.H.... Choi J.	2005	PML
30	Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in hepatocellular carcinoma and metastatic liver cancer. (15254700)	Hotta T.... Tsubota Y.T.	2004	DPYD, TYMP
31	Role of nucleostemin in growth regulation of gastric cancer, liver cancer and other malignancies. (15112336)	Liu S.J.... Lao W.D.	2004	GNL3
32	Anti-liver cancer activity of TNF-related apoptosis-i nducing ligand gene and its bystander effects. (14991932)	He C.... Fang B.L.	2004	TNFSF10
33	Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. (15349899)	Yokoo H.... Hirohashi S.	2004	AFP
34	Clinical values of vascular endothelial growth factor expression and microvascular density analysis in liver cancer specimens (14980110)	YAO D.F.... Qiu L.W.	2004	VEGFA
35	Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. (12813464)	Paterlini-Brechot P.... Brechot C.	2003	TERT, ITPR1, ITPR2
36	CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. (12569554)	Silvestri L.... Silini E.M.	2003	CYP1A1, CYP2D6, CYP1A2
37	Magnolol suppresses proliferation of cultured human c olon and liver cancer cells by inhibiting DNA synthesis and activating apoptosi s. (11813258)	Lin S.Y.... Lee W.S.	2002	CDKN1A
38	Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. (12450215)	He H.... Zhao S.Y.	2002	SAR1B, RAB4B, ARL5A
39	Analysis of the beta-catenin/T cell factor signaling pathway in 36 gastrointestinal and liver cancer cells. (12460462)	Ikenoue T.... Omata M.	2002	CTNNB1, TCF4
40	Liver cancer. (11385973)	Aguayo A.... Patt Y.Z.	2001	IFNA1
41	Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. (10915728)	Ikeda K.... Kumada H.	2000	IFNA1
42	Inhibition of proliferation, invasion and adhesion of liver cancer cells by 5-azacytidine and butyrate. (10652571)	Wang X.M.... Evers B.M.	1999	CDKN1B
43	Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer. (9869396)	Akahane T.... Toyota T.	1998	PLAUR
44	Serum transforming growth factor-alpha level can be a parameter for evaluating liver regeneration after partial hepatectomy in patients with liver cancer. (9151911)	Tomiya T.... Fujiwara K.	1997	HGF, TGFA
45	Diagnosis of primary liver cancer using lectin affinity chromatography of serum alkaline phosphatase. (9148865)	Lu Y.... Chen H.L.	1997	ALPP, KHDRBS3
46	The altered activity of membrane-bound protein kinase C in human liver cancer. (8697446)	Chang K.J.... Liu J.Y.	1996	DYT10
47	Viral co-factors in liver cancer: lessons from hepati tis B virus. (8875624)	Butel J.S.... Slagle B.L.	1995	DDB1
48	Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with alpha-fetoprotein. (1372529)	Huber K.... Binder B.R.	1992	AFP
49	Resection of the primary liver cancer of the hepatic hilus. (1846775)	Yu Y.Q.... Lu J.Z.	1991	HSPG2
50	A study of alpha-fetoprotein in primary liver cancer in Tanzania. (1722452)	Spencer S.S.... Nantulya V.M.	1991	AFP

Genes related to liver cancer according to GeneCards:

(show top 50)    (show all 356)

id	Symbol	Description	Score	GeneCards Section Context
1	DLC1	deleted in liver cancer 1	11.0	Orthologs, Publications, Transcripts, Aliases & Descriptions (show all 5 sections) Functions
2	ASAP3	ArfGAP with SH3 domain, ankyrin repeat and PH domain 3	11.0	Aliases & Descriptions
3	CHD1L	chromodomain helicase DNA binding protein 1-like	11.0	Publications, Aliases & Descriptions
4	LCO	liver cancer oncogene	11.0	Aliases & Descriptions, Functions
5	HULC	highly up-regulated in liver cancer (non-protein coding)	11.0	Transcripts, Aliases & Descriptions
6	PPIAL4B	peptidylprolyl isomerase A (cyclophilin A)-like 4B	11.0	Aliases & Descriptions
7	PPIAL4C	peptidylprolyl isomerase A (cyclophilin A)-like 4C	11.0	Aliases & Descriptions
8	PPIAL4A	peptidylprolyl isomerase A (cyclophilin A)-like 4A	11.0	Aliases & Descriptions
9	STARD8	StAR-related lipid transfer (START) domain containing 8	11.0	Publications, Aliases & Descriptions
10	STARD13	StAR-related lipid transfer (START) domain containing 13	11.0	Aliases & Descriptions, Publications
11	JST	tumor suppressor gene JST	10.9	Publications
12	MIR375	microRNA 375	10.9	Publications
13	MIR26B	microRNA 26b	10.9	Publications
14	MIR26A1	microRNA 26a-1	10.9	Publications
15	RBMY1D	RNA binding motif protein, Y-linked, family 1, member D	10.9	Publications
16	RAB4B	RAB4B, member RAS oncogene family	10.9	Publications
17	RBMY1B	RNA binding motif protein, Y-linked, family 1, member B	10.9	Publications
18	RBMY1E	RNA binding motif protein, Y-linked, family 1, member E	10.9	Publications
19	MIR122	microRNA 122	10.9	Publications
20	TENC1	tensin like C1 domain containing phosphatase (tensin 2)	10.9	Publications
21	RBMY1J	RNA binding motif protein, Y-linked, family 1, member J	10.9	Publications
22	RBMY1F	RNA binding motif protein, Y-linked, family 1, member F	10.9	Publications
23	GNMT	glycine N-methyltransferase	10.9	Publications
24	MAT2A	methionine adenosyltransferase II, alpha	10.9	Publications
25	REG3A	regenerating islet-derived 3 alpha	10.9	Publications
26	MAGEC2	melanoma antigen family C, 2	10.9	Expressions
27	PARG	poly (ADP-ribose) glycohydrolase	10.9	Publications
28	FGF19	fibroblast growth factor 19	10.9	Publications
29	GAL3ST1	galactose-3-O-sulfotransferase 1	10.9	Publications
30	PHF19	PHD finger protein 19	10.9	Expressions
31	DERL2	derlin 2	10.9	Publications
32	RBMY1A1	RNA binding motif protein, Y-linked, family 1, member A1	10.9	Publications
33	MAT1A	methionine adenosyltransferase I, alpha	10.9	Publications
34	RPE	ribulose-5-phosphate-3-epimerase	10.9	Publications
35	ARHGAP1	Rho GTPase activating protein 1	10.9	Publications
36	TP53I11	tumor protein p53 inducible protein 11	10.9	Publications
37	PCBD1	pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha	10.9	Publications
38	TNS4	tensin 4	10.9	Publications
39	DVL3	dishevelled, dsh homolog 3 (Drosophila)	10.9	Publications
40	SAR1B	SAR1 homolog B (S. cerevisiae)	10.9	Publications
41	ARL5A	ADP-ribosylation factor-like 5A	10.9	Publications
42	NDRG2	NDRG family member 2	10.9	Publications, Expressions
43	IL22RA1	interleukin 22 receptor, alpha 1	10.9	Publications
44	AFP	alpha-fetoprotein	10.9	Publications
45	MAT2B	methionine adenosyltransferase II, beta	10.9	Publications
46	YY1AP1	YY1 associated protein 1	10.9	Publications
47	RCN1	reticulocalbin 1, EF-hand calcium binding domain	10.9	Publications
48	TAGLN2	transgelin 2	10.9	Publications
49	TFPT	TCF3 (E2A) fusion partner (in childhood Leukemia)	10.9	Publications
50	TFPI2	tissue factor pathway inhibitor 2	10.9	Publications

Pathways related to liver cancer according to GeneDecks:

(show top 50)    (show all 362)

id	Pathway	Score	Top Affiliating Genes
1	Apoptosis and Autophagy3	11.1	SERPINB5, LMNB1, MYC, MYCN, BID, BIRC2
2	Akt Signaling36	11.0	PIK3CG, RAF1, LIF, CHUK, YAP1, CDC37
3	Signal transduction AKT signaling10	10.9	IRS1, IKBKB
4	EGFR Inhibitor Pathway, Pharmacodynamics34	10.9	HRAS, NRAS
5	Cell cycle_ESR1 regulation of G1/S transition41	10.4	RB1, RBL2, MYC, UBC, XPO1, CDKN1A
6	Breast Cancer Regulation by Stathmin136	10.3	RAF1, RAC1, ITPR1, ITPR2, FGF19, FGF2
7	TGF-beta Signaling Pathways37	10.3	PIK3CG, MYC, RAF1, RAC1, FOS, MAPK8
8	p53 Signaling36	10.2	BCL2, UBC, BAX, CDKN1A, CDK4, FOS
9	Signal transduction_AKT signaling41	10.2	MYC, BCL2L1, CHUK, BAX, CDKN1A, CDKN1B
10	Apoptosis20	10.1	PIK3CG, BID, BIRC2, BCL2, BCL2L1, CHUK
11	PEDF Induced Signaling36	10.1	BMP6, RAF1, LIF, BCL2, BCL2L1, CHUK
12	STAT3 Pathway36	10.0	MYC, BMP6, RAF1, RAC1, LIF, BCL2
13	Transcription_Androgen Receptor nuclear signaling41	10.0	RAF1, FZD7, CDKN1A, IL6, MAPK1, MAP2K1
14	eNOS Signaling36	9.9	BMP6, ITPR1, ITPR2, AREG, INSR, FGF19
15	Cell cycle20	9.9	RB1, RBL2, MYC, CDKN1A, CDKN1B, CDKN2A
16	Development_EGFR signaling pathway41	9.8	MYC, RAF1, RAC1, CHUK, FOS, AREG
17	14-3-3 Induced Intracellular Signaling36	9.8	RAF1, YAP1, FLT1, AREG, INSR, FGF19
18	Development Prolactin receptor signaling10	9.8	MYC, RAF1, RAC1, BCL2, BCL2L1, IRS1
19	Development_Prolactin receptor signaling41	9.8	MYC, RAF1, RAC1, BCL2, BCL2L1, IRS1
20	PAK Pathway36	9.8	BMP6, RAC1, LIF, KDR, BCL2, BAX
21	Development IGF-RI signaling10	9.8	MYC, RAF1, BCL2L1, CHUK, IRS1, MAPK1
22	Chronic myeloid leukemia20	9.7	PIK3CG, RB1, MYC, RAF1, BCL2L1, CHUK
23	Epithelial Adherens Junctions36	9.7	BMP6, RAC1, CHUK, CDH1, AREG, FGF19
24	Non-small cell lung cancer20	9.6	PIK3CG, RB1, RAF1, RASSF1, CDKN2A, CDK4
25	Paxillin Interactions36	9.6	RAC1, KDR, ITGA7, ITGB1, FLT1, AREG
26	Translation_Non-genomic (rapid) action of Androgen Receptor41	9.6	RAF1, FZD7, IRS1, MAPK1, MAP2K1, CAV1
27	Antioxidant Action of Vitamin-C36	9.6	BMP6, RAC1, LIF, KDR, BCL2, CHUK
28	DHA Signaling36	9.4	BMP6, BID, KDR, BCL2, BCL2L1, BAX
29	Telomerase Components in Cell Signaling36	9.4	RB1, MYC, BMP6, KDR, FLT1, AREG
30	Rho Family GTPases36	9.4	BMP6, RAF1, RAC1, LIF, KDR, BCL2
31	Cytokine-cytokine receptor interaction20	9.4	VEGFA, LIF, KDR, FLT1, MET, IL13
32	eIF2 Pathway36	9.3	BMP6, RAF1, AREG, INS, INSR, FGF19
33	G12-G13 in Cellular Signaling36	9.2	RAF1, RAC1, CHUK, AXIN1, FZD7, CDH13
34	Small cell lung cancer20	9.2	PIK3CG, RB1, MYC, RARB, BIRC2, BCL2
35	EGF Pathway36	9.2	MYC, RAF1, RAC1, CHUK, CDH1, FOS
36	Apoptotic Pathways in Synovial Fibroblasts36	9.2	BMP6, KDR, CFLAR, FLT1, AREG, FGF19
37	p53 Mediated Apoptosis36	9.1	BMP6, BID, KDR, BCL2, BAX, FLT1
38	TGF-Beta Pathway36	9.1	BMP6, KDR, BCL2, BAX, CDH1, FOS
39	Bladder cancer20	9.0	RB1, VEGFA, MYC, RAF1, RASSF1, CDKN1A
40	MAPK signaling pathway20	9.0	MYC, RAF1, RAC1, CHUK, FOS, FGF19
41	Tec Kinases Signaling36	9.0	BMP6, RAC1, BCL2, BAX, ITGA7, ITGB1
42	Chagas disease (American trypanosomiasis)20	8.9	PIK3CG, CHUK, CFLAR, FOS, IL2, IL6
43	NFAT in Immune Response36	8.9	BMP6, KDR, CHUK, XPO1, ITPR1, ITPR2
44	Rap1 Pathway36	8.8	BMP6, RAF1, ITGA7, ITGB1, ITPR1, ITPR2
45	Renin-Angiotensin Pathway36	8.7	BMP6, RAF1, RAC1, KDR, CHUK, ITPR1
46	Activation of PKC through GPCR36	8.5	BMP6, RAF1, RAC1, KDR, ITPR1, ITPR2
47	p70S6K Signaling36	8.4	BMP6, RAF1, RAC1, KDR, IRS1, FLT1
48	Pathways in cancer20	8.2	PIK3CG, RB1, VEGFA, MYC, RARB, RASSF1
49	Estrogen Pathway36	8.1	BMP6, RAF1, KDR, BCL2, CHUK, FOS
50	Pancreatic Adenocarcinoma36	7.7	RB1, BMP6, RAF1, RAC1, BIRC5, KDR

Compounds related to liver cancer according to GeneDecks:

(show top 50)    (show all 517)

id	Compound	Score	Top Affiliating Genes
1	leucine32	11.2	RB1, MYC, MYCN, RAC1, CLEC12A, CHUK
2	carbon32	11.0	CEACAM3, CDKN3, GSTP1, FAS, ALDH9A1, GLUL
3	roscovitine32	10.9	PIK3CG, BIRC5, PARP1, BCL2L1, XIAP, CDC25A
4	atp32	10.9	RB1, RBL2, SETD2, RAC1, LIF, BIRC5
5	vincristine32 34 9 9	13.8	MYCN, FGF2, MAD2L1, IFNA1, IFNB1, ALDH1A1
6	dmso32	10.8	BMP6, MUC5AC, XDH, ITPR1, INSR, MAP2K1
7	palmitate32	10.6	LIPA, S100A6, IRS1, APOA1, IKBKB, HSPG2
8	cysteine32	10.5	SERPINA1, NAT1, NAT2, LMNB1, RARB, RAF1
9	chloramphenicol32 9 9	12.5	SETD2, MYC, MYCN, RARB, RAF1, CDKN2A
10	nocodazole32 42 9 9	13.5	PIN1, RAF1, RAC1, BIRC5, CDKN1A, CDKN3
11	cyclic amp32 18	11.4	RB1, SETD2, RARB, LIF, BID, CDKN1B
12	calcium32 9 18 9	13.4	PIN1, REG1A, RELN, RCN1, RB1, RAC1
13	12-o-tetradecanoylphorbol 13-acetate32	10.3	RB1, MYC, BMP6, RARB, RAF1, LIF
14	nitric oxide32 9 18 9	13.1	RB1, SERPINB5, SERPINA1, NAT1, NAT2, MYCN
15	camptothecin32 42 9 9	13.1	PIK3CG, RB1, SETD2, MYC, BID, BIRC5
16	adpribose32	10.1	PIK3CG, RB1, LMNB1, BID, BIRC5, PARP1
17	dihydrotestosterone32 9 18 9	13.1	SETD2, BMP6, CDK4, AREG, INSR, FGF2
18	glycerol32 9 18 9	13.0	CHUK, ITPR1, IRS1, INS, INSR, GSTP1
19	1,25 dihydroxy vitamin d332	9.9	RB1, MYC, BMP6, RAF1, LIF, CDKN1B
20	gp 13032	9.9	BMP6, LIF, BCL2L1, IL13, FAS, MAP2K1
21	vinblastine32 9 9	11.9	RAF1, BIRC5, KDR, BCL2, BCL2L1, MVP
22	cholesterol32 9 18 9	12.8	RELN, RB1, SERPINA1, NAT2, RAC1, LIF
23	progestin32	9.8	VEGFA, LIF, KDR, S100A6, CDK4, CDH1
24	formaldehyde32 18	10.7	RB1, CDKN1B, CDKN3, CDH1, APOA1, CCND1
25	arachidonic acid32 9 18 9	12.7	SERPINA1, RAC1, LIPF, LIF, LIPA, BCL2L1
26	manumycin32	9.6	RAF1, CHUK, INSR, MAPK8, MAP2K1, HRAS
27	ifn-alpha32	9.5	LIF, CDKN2A, IL13, IL2, IL6, FAS
28	phosphotyrosine32	9.5	PIK3CG, RAF1, RAC1, KDR, MUC5AC, CDKN3
29	okadaic acid32 42	10.5	RB1, MYC, BMP6, RAF1, BCL2, BCL2L1
30	15-deoxy-delta-12,14-prostaglandin j232	9.5	PIK3CG, VEGFA, MYC, BMP6, BIRC2, BIRC5
31	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide32	9.4	MYC, PARP1, BCL2, BCL2L1, BAX, MET
32	sulindac32 9 9	11.4	BIRC5, BCL2, BCL2L1, BAX, XIAP, CDKN1A
33	thymidine32 18	10.4	REG1A, REG3A, RB1, SERPINA1, BOK, MYC
34	ibmx32	9.3	RARB, RAF1, CDKN3, FN1, IRS1, INS
35	prednisolone32 9 9	11.1	MYC, BMP6, MVP, CDKN3, FGF2, IL13
36	adriamycin32	9.1	RB1, MYC, MYCN, BIRC2, BIRC5, BCL2
37	oxaliplatin32 34 9 9	12.0	VEGFA, BIRC5, BCL2L1, XIAP, CFLAR, CEACAM5
38	methotrexate32 34 42 9 9	13.0	RB1, NAT2, BMP6, BIRC5, MUC5AC, CEACAM3
39	thymidylate32	8.9	RB1, VEGFA, BIRC5, BCL2, BCL2L1, MVP
40	arsenite32 18	9.7	PIK3CG, SETD2, VEGFA, MYC, RAC1, BIRC2
41	docetaxel32 34 9 9	11.6	SETD2, VEGFA, MYC, RAF1, BID, BIRC2
42	trastuzumab32 34 9 9	11.6	PIK3CG, RAF1, BIRC5, KDR, CDKN1B, CDKN3
43	bortezomib32 9 9	10.6	SETD2, VEGFA, MYC, BID, BIRC5, PARP1
44	hydrocortisone32 9 9	10.6	BMP6, LIF, KDR, FLT1, INS, INSR
45	imatinib32 34 9 9	11.5	PIK3CG, VEGFA, MYC, BMP6, RAF1, BID
46	calcitriol32 42 9 18 9	12.3	RB1, MYC, BMP6, RARB, LIF, XPO1
47	diphenyleneiodonium32	8.2	SETD2, VEGFA, RAC1, XDH, CDKN3, INSR
48	paraffin32	7.6	RB1, SERPINB5, SERPINA1, VEGFA, MYC, MYCN
49	curcumin32	7.5	PIK3CG, NAT1, VEGFA, MYC, RAF1, BID
50	tamoxifen32 34 9 9	10.4	SERPINB5, VEGFA, MYC, BMP6, RAF1, BIRC5

Cellular components related to liver cancer according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	cytosol	GO:005829	11.4	IL22RA2, ALDH1A1, ALDH9A1, GNMT, HSPB1, CASP3
2	nucleoplasm	GO:005654	11.1	YAP1, XRCC5, XPO1, CDKN1A, CDKN1B, CDKN2A
3	cytoplasm	GO:005737	10.4	NDRG2, RUNX3, WNT1, ADAM17, ADAM9, HDAC9
4	nucleus	GO:005634	10.4	CCND2, HMBS, ERBB2, TRIB3, TP53, TPI1
5	focal adhesion	GO:005925	10.2	TENC1, PTK2, DLC1, STARD8, ADAM17, EPHX2
6	cell surface	GO:009986	9.9	TIMP2, TGFA, TGFB1, PRLR, PROM1, CXCR4
7	caveola	GO:005901	8.9	SRC, DLC1, PTGS2, CAV1, MAPK1, INSR
8	extracellular space	GO:005615	8.2	DPYSL3, OSM, PROM1, SOD1, CP, ADAM9
9	plasma membrane	GO:005886	7.8	SRC, SPRY2, CTNNB1, NRAS, SMAD3, SMAD7

Biological processes related to liver cancer according to GeneDecks:

(show top 50)    (show all 70)

id	Name	GO ID	Score	Top Affiliating Genes
1	cell proliferation	GO:008283	11.3	REG3A, BOK, RAF1, LIPA, BCL2L1, YAP1
2	organ regeneration	GO:031100	11.2	LIF, LEF1, CDKN1A, ANGPT2, ANXA3, CCND1
3	xenobiotic metabolic process	GO:006805	11.1	NAT1, NAT2, GSTP1, MAT2A, MAT1A, MAT2B
4	small molecule metabolic process	GO:044281	11.0	PIK3CG, PCBD1, NAT1, NAT2, XDH, ITPR1
5	activation of MAPKK activity	GO:000186	10.9	RAF1, NRAS, ADAM9, GADD45B
6	transforming growth factor beta receptor signaling pathway	GO:007179	10.9	MYC, PARP1, UBC, XPO1, FOS, TP53
7	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:006919	10.7	BOK, MYC, BAX, XDH, CDKN1B, CDKN2A
8	negative regulation of transcription from RNA polymerase II promoter	GO:000122	10.7	MYC, RARB, ZFP36, PARP1, LEF1, UBC
9	positive regulation of fibroblast proliferation	GO:048146	10.7	MYC, S100A6, CDKN1A, CDK4, PDGFB, PDGFRA
10	cellular response to insulin stimulus	GO:032869	10.7	PARP1, IRS1, INSR, FBP1, CCND2, AKT1
11	response to estradiol stimulus	GO:032355	10.6	SERPINA1, BID, INSR, CCND2, CASP8, HMBS
12	phosphatidylinositol-mediated signaling	GO:048015	10.6	CHUK, CDKN1B, IRS1, IGF1R, CASP9, AKT1
13	response to organic cyclic compound	GO:014070	10.6	SERPINA1, LEF1, MSH2, CDKN1A, MET, ANGPT2
14	induction of apoptosis	GO:006917	10.5	BOK, BAX, CDKN1B, CDKN2A, FAS, MAPK1
15	release of cytochrome c from mitochondria	GO:001836	10.5	MYC, BID, BCL2, BCL2L1, BAX, CASP3
16	positive regulation of protein phosphorylation	GO:001934	10.4	PIN1, VEGFA, AXIN1, INSR, CCND2, CCND1
17	induction of apoptosis by intracellular signals	GO:008629	10.4	MYC, BID, BCL2, BCL2L1, BAX, XIAP
18	positive regulation of peptidyl-serine phosphorylation	GO:033138	10.4	SFRP2, VEGFA, RAF1, LIF, BCL2, AXIN1
19	activation of pro-apoptotic gene products	GO:008633	10.3	MYC, BID, BCL2, BAX, FADD, FAS
20	negative regulation of cell growth	GO:030308	10.3	SFRP2, RB1, BCL2, CDKN1A, CDKN1B, CDKN2A
21	mammary gland alveolus development	GO:060749	10.3	CHUK, CCND1, TNFRSF11A, TNFSF11, EGF, TGFA
22	apoptotic process	GO:006915	10.2	BOK, LMNB1, RAF1, RAC1, BID, BIRC2
23	positive regulation of transcription, DNA-dependent	GO:045893	10.1	RB1, MYC, LEF1, AXIN1, FZD7, CDKN2A
24	response to DNA damage stimulus	GO:006974	10.1	MYC, RASSF1, PARG, BCL2, CHD1L, BAX
25	cell cycle arrest	GO:007050	10.1	RB1, MYC, RASSF1, MSH2, CDKN1A, CDKN1B
26	fibroblast growth factor receptor signaling pathway	GO:008543	10.1	RAF1, CHUK, UBC, CDKN1B, ITPR1, ITPR2
27	anti-apoptosis	GO:006916	10.1	BIRC2, BIRC5, BCL2, BCL2L1, UBC, XIAP
28	positive regulation of cell growth	GO:030307	9.9	SFRP2, BCL2, LEF1, MMP14, INS, IL2
29	nerve growth factor receptor signaling pathway	GO:048011	9.9	RAF1, RAC1, CHUK, UBC, CDKN1B, ITPR1
30	virus-host interaction	GO:019048	9.8	RB1, CLDN1, KDR, BAX, XPO1, CFLAR
31	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	9.6	RELN, KDR, FLT1, INS, CCL5, F2
32	insulin receptor signaling pathway	GO:008286	9.6	RAF1, IRS1, INS, INSR, FGF19, FGF2
33	Ras protein signal transduction	GO:007265	9.6	RB1, RAF1, RASSF1, CDKN1A, CDKN2A, FGF2
34	positive regulation of protein kinase B signaling cascade	GO:051897	9.6	PIK3CG, MTDH, INS, INSR, IGF2, AKR1C2
35	epidermal growth factor receptor signaling pathway	GO:007173	9.6	RAF1, CHUK, UBC, CDKN1B, ITPR1, ITPR2
36	response to drug	GO:042493	9.5	SFRP2, MYC, BCL2, MVP, XPO1, MSH2
37	positive regulation of transcription from RNA polymerase II promoter	GO:045944	9.5	SFRP2, RB1, VEGFA, MYC, MYCN, BMP6
38	platelet degranulation	GO:002576	9.5	SERPINA1, VEGFA, FN1, APOA1, ALB, HSPA5
39	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	9.5	RELN, VEGFA, LIF, ITGB1, INS, IL6
40	positive regulation of cell proliferation	GO:008284	9.4	REG1A, SFRP2, VEGFA, MYC, LIF, BIRC5
41	negative regulation of cell proliferation	GO:008285	9.4	SFRP2, RARB, RAF1, LIF, CDKN1A, CDKN1B
42	positive regulation of MAPK cascade	GO:043410	9.4	LIF, KDR, ITGB1, FLT1, INS, INSR
43	positive regulation of apoptotic process	GO:043065	9.3	SFRP2, RARB, BID, BAX, ITGB1, APC
44	negative regulation of apoptotic process	GO:043066	9.2	PIK3CG, VEGFA, MYC, RAF1, BIRC2, KDR
45	MAPK cascade	GO:000165	9.2	MYC, RAF1, INS, MAPK1, MAP2K1, CCL5
46	platelet activation	GO:030168	8.9	PIK3CG, SERPINA1, VEGFA, RAF1, RAC1, ITPR1
47	positive regulation of NF-kappaB transcription factor activity	GO:051092	8.9	CHUK, UBC, MTDH, INS, IL6, IKBKB
48	response to hypoxia	GO:001666	8.8	SERPINA1, VEGFA, RAF1, BCL2, ITPR1, ITPR2
49	blood coagulation	GO:007596	8.7	PIK3CG, SERPINA1, VEGFA, RAF1, RAC1, CD47
50	positive regulation of cell migration	GO:030335	8.5	VEGFA, KDR, LEF1, CDH13, ITGB1, MMP14

Molecular functions related to liver cancer according to GeneDecks:

(show all 10)

id	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase binding	GO:019901	10.8	SOCS1, IKBKB, CCND1, CCND2, CCNA2, CCNB1
2	transcription regulatory region DNA binding	GO:044212	10.7	SMAD7, PHB, NFKB1, WT1, HIF1A, AHR
3	protein binding	GO:005515	10.4	TGFBR2, NDRG2, KRT18, KRT7, WT1, RHOA
4	cytokine activity	GO:005125	9.9	IFNB1, TNFRSF11B, TNFSF10, TNFSF11, SPP1, OSM
5	transcription factor binding	GO:008134	9.9	SMAD3, HIF1A, AHR, TWIST1, DNMT1, STAT3
6	growth factor activity	GO:008083	9.8	PDGFB, EGF, TYMP, TGFA, TGFB1, OSM
7	protein homodimerization activity	GO:042803	9.7	RNF17, NFKB1, RPE, NOS2, CRYL1, SMAD4
8	identical protein binding	GO:042802	9.6	FAS, IGF1R, CASP8, GLUL, AKT1, ERBB2
9	protein heterodimerization activity	GO:046982	9.6	HIF1A, EGFR, PDGFB, TP53, ERBB2, AHR
10	enzyme binding	GO:019899	9.1	PTGS2, CYB5A, CYP1A2, CYP3A4, CYP2E1, CTNNB1